Retatrutide is a triple-agonist investigational drug in phase 3 clinical trials. Phase 2 data suggest up to 24% mean weight reduction at 48 weeks. It’s not yet FDA-approved — current GLP-1 options, subject to evaluation by a licensed provider, are at TelosRX.
Retatrutide weight loss research has drawn significant attention across metabolic medicine. The GLP-1 class keeps evolving. Semaglutide targeted one receptor. Tirzepatide hit two. Retatrutide targets three. Here’s what the actual trial data show.
What Is Retatrutide?
Retatrutide — also called LY3437943 — is a single-molecule peptide developed by Eli Lilly. It activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. That triple-receptor design is why researchers call it a “triple agonist.”
In clinical trials, it’s delivered as a once-weekly subcutaneous injection. Retatrutide is not FDA-approved and is not commercially available. Phase 3 TRIUMPH trials are currently ongoing.
One critical regulatory note: the FDA has explicitly stated that retatrutide cannot be used in compounding under current federal regulations. Unlike semaglutide and tirzepatide during their shortage periods, retatrutide has no compounding pathway at this time.
How Retatrutide Works: Three Receptors at Once
Each receptor retatrutide targets does a distinct job. Understanding how they work together explains the weight loss signal seen in trials.
GLP-1 (glucagon-like peptide-1): Triggers insulin release after meals. Slows gastric emptying. Reduces appetite signals in the brain. This is the same mechanism used by semaglutide.
GIP (glucose-dependent insulinotropic polypeptide): Amplifies insulin response. Appears to enhance fat metabolism and may reduce GI side effects from GLP-1 activity. Adding GIP to GLP-1 is what makes tirzepatide outperform semaglutide in published comparisons.
Glucagon receptor: Increases energy expenditure and promotes fat breakdown. Glucagon normally raises blood sugar. But combined with GLP-1 and GIP activation, the net effect in trials kept blood glucose stable while capturing glucagon’s metabolic output.
The result in early clinical data: greater caloric deficit than single or dual-receptor approaches alone. Each layer compounds the appetite and metabolic effects of the others.
Retatrutide Clinical Trial Results
The landmark data come from a phase 2 randomized controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023). It enrolled 338 adults with obesity or overweight. Participants received weekly subcutaneous retatrutide or placebo for 48 weeks.
Key weight outcomes at 48 weeks:
- 12 mg dose: 24.2% mean weight reduction from baseline
- 8 mg dose: 23.9% mean weight reduction
- 4 mg dose: approximately 17.8% mean weight reduction
- 1 mg dose: 8.7% mean weight reduction
- Placebo: 2.1%
Beyond weight outcomes, phase 2 data showed meaningful cardiometabolic improvements at 48 weeks. Among participants who began with prediabetes, 72% in the retatrutide groups achieved normoglycemia (HbA1c below 5.7%), versus 22% in the placebo group. Blood pressure, triglycerides, and insulin sensitivity also improved significantly across dosing groups.
Phase 3 data came from the TRIUMPH phase 3 program. A trial in participants with obesity and osteoarthritis of the knee found 28.7% mean weight loss at 12 mg over 68 weeks — roughly 71 lbs per participant on average at the highest dose. These are efficacy estimates under controlled trial conditions. Treatment-regimen estimates at the same dose were approximately 23.7%. Individual results in real-world practice will vary.
Retatrutide vs. Tirzepatide vs. Semaglutide
Here’s how the three drugs compare across key characteristics. No direct head-to-head trial exists. These figures come from separate trials with different populations and durations — cross-trial comparisons require caution.
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide (LY3437943) |
|---|---|---|---|
| Receptors targeted | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Dosing frequency | Once weekly | Once weekly | Once weekly (in trials) |
| Approximate half-life | ~7 days | ~5 days | ~6 days |
| Peak phase 2 weight loss | ~15% at 72 weeks | ~21% at 72 weeks | ~24% at 48 weeks |
| FDA approval status | Approved (obesity, diabetes) | Approved (obesity, diabetes) | Not FDA-approved |
| Compounding status | Shortage-dependent | Shortage-dependent | FDA-prohibited |
| Common side effects | Nausea, diarrhea, constipation | Nausea, diarrhea, constipation | Nausea, diarrhea, dysesthesia |
Retatrutide Side Effects: What the Trials Found
Phase 2 and phase 3 data show a side effect profile largely consistent with other GLP-1-class drugs — with one notable exception.
Common side effects in trials (mild to moderate, dose-dependent):
- Nausea
- Diarrhea (approximately 33–35% of participants at the highest doses in phase 3, versus 13% with placebo)
- Vomiting
- Constipation
Dysesthesia — abnormal skin sensations including tingling, itching, or pain on touch — appeared in approximately 21% of participants at the highest phase 3 dose. With tirzepatide, the same symptom appeared in roughly 0.4% of participants. This difference is significant and is being monitored in ongoing trials.
Discontinuation rates reached approximately 18% at the 12 mg dose in phase 3 data. That compares to about 4.5% for semaglutide and 7% for tirzepatide in their respective phase 3 trials. Some discontinuations were attributed to participants at lower starting BMI losing more weight than intended.
Heart rate increases were dose-dependent in phase 2, consistent with glucagon receptor activation. Serious adverse events were rare and occurred at similar rates to placebo in both phase 2 and phase 3 data reviewed to date.
When Will Retatrutide Be FDA Approved?
Eli Lilly’s TRIUMPH program includes multiple ongoing phase 3 trials: TRIUMPH-1 (obesity without diabetes), TRIUMPH-2 (type 2 diabetes), and additional trials in kidney disease, cardiovascular risk, and osteoarthritis.
TRIUMPH-1 was originally expected to complete in 2026. Once Eli Lilly submits a New Drug Application, FDA review typically takes 6–10 months. A realistic approval window, assuming on-schedule completion, is late 2026 to 2027. That timeline depends on trial completion, data review, and regulatory processes — none of which are guaranteed.
Retatrutide is not on the FDA’s drug shortage list. The FDA has explicitly stated it cannot be compounded under current federal law.
Current GLP-1 Options Available Through Telehealth
Retatrutide isn’t accessible yet. But for people pursuing weight management goals today, two FDA-approved GLP-1 drugs have been available through compounding in shortage contexts: tirzepatide and semaglutide.
Compounded tirzepatide — the dual GLP-1/GIP agonist — showed approximately 21% mean weight loss in its own phase 3 trials. Compounded semaglutide remains a well-studied option with a long safety record. Both are subject to evaluation by a licensed provider and are not guaranteed for every individual.
If you’re comparing the two, TelosRX’s asynchronous evaluation process lets a licensed provider review your health profile without requiring a scheduled appointment. You submit your information, the provider reviews it, and a determination is made — no waiting room required. See tirzepatide vs. semaglutide compared for a deeper look.
When retatrutide receives FDA approval — if it does — its clinical role will likely be as a next-step option for patients who don’t respond adequately to existing therapies. The current data from peer-reviewed clinical literature is promising but not yet confirmed at scale across all phase 3 populations.
Frequently Asked Questions
What is retatrutide used for?
Retatrutide is under investigation for weight loss, type 2 diabetes, chronic kidney disease, liver disease (MASH), osteoarthritis of the knee, and cardiovascular risk reduction. It is not FDA-approved for any indication as of 2026. All applications remain in phase 3 clinical trials.
How does retatrutide cause weight loss?
Retatrutide activates three hormone receptors. GLP-1 reduces appetite and slows digestion. GIP amplifies insulin response and fat metabolism. Glucagon increases energy expenditure and promotes fat breakdown. The combination of all three appears to produce greater caloric reduction than single or dual-receptor drugs, based on phase 2 trial data.
Is retatrutide more effective than tirzepatide?
Phase 2 data suggest retatrutide may produce greater weight loss than tirzepatide — roughly 24% versus 21% at comparable timepoints — but no direct head-to-head trial exists. Retatrutide also shows a higher discontinuation rate and a unique side effect profile, including dysesthesia. Making a definitive comparison requires more data from phase 3.
When will retatrutide be available?
Eli Lilly is running TRIUMPH phase 3 trials with primary completion expected in 2026. If data support a New Drug Application and the FDA approves it on schedule, commercial availability could begin in late 2026 or 2027. This timeline is not guaranteed and depends on regulatory outcomes.
Can compounding pharmacies make retatrutide?
No. The FDA has explicitly stated that retatrutide cannot be used in compounding under current federal law. It has no FDA shortage designation — the mechanism that allowed compounded tirzepatide and semaglutide. Any compounded retatrutide would be unlawful and unverified for dosing accuracy and safety.
What are retatrutide’s side effects?
Common side effects in trials include nausea, diarrhea, vomiting, and constipation — typical for GLP-1-class drugs. Dysesthesia (abnormal skin sensations like tingling or itching) occurred in approximately 21% of participants at the highest phase 3 dose, notably higher than the 0.4% seen with tirzepatide. Side effects were generally mild to moderate in severity.
Is retatrutide FDA-approved?
No. Retatrutide is not FDA-approved as of May 2026. It is an investigational drug in phase 3 trials. It cannot legally be prescribed or compounded in the United States at this time.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.